At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Hyman Muss, MD, of the University of North Carolina, Chapel Hill, NC, provides an update on the CALGB/CTSU/Alliance 49907 trial, which compared capecitabine with standard chemotherapy in patients with breast cancer who were at least 65 years old.
CALGB 49907 trial: Standard chemotherapy versus capecitabine for older women with breast cancer
Related To This Subject
Share